Method of treatment of attention deficit/hyperactivity disorder (adhd)

Abstract

The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.

What is claimed is: 
     
         1 . A method for treatment of ADHD in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a formulation of viloxazine. 
     
     
         2 . The method of  claim 1 , wherein the therapeutically effective amount is from about 10 to about 600 mg a day. 
     
     
         3 . The method of  claim 1 , wherein the human subject is a human child. 
     
     
         4 . The method of  claim 2 , which provides an improved adverse effect profile. 
     
     
         5 . A method for treatment of ADHD in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of a pharmaceutical agent exhibiting 5HT1B and/or 5HT7 antagonistic activity. 
     
     
         6 . A method for treatment of ADHD in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of a pharmaceutical agent exhibiting combined noradrenergic reuptake inhibitory activity and a 5HT1B or 5HT7 antagonistic activity. 
     
     
         7 . A method for treatment of ADHD in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of a pharmaceutical agent exhibiting combined noradrenergic reuptake inhibitory activity and α 4 /β 2  and/or α7 antagonistic activity. 
     
     
         8 . A method for treatment of ADHD in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of a pharmaceutical agent exhibiting combined 5HT1B and/or 5HT7 antagonistic activity and α 4 /β 2  and/or α7 antagonistic activity.